Thus, targeting the PR with an antiprogestin like MIF along with antiestrogen therapy should have added benefit for all ER+ breast cancer patients, and particular benefit for patients with ER+, antiestrogen-unresponsive tumors. This evidence concerns the gene MIF and breast carcinoma.